Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Claudio Bassi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5416-329X; OpenAlex author ID A5074748035, A5107837866. Sources: OpenAlex.

Their work

Papers
109 (first author 3, last author 24)
Trials
0
Grants
0
Labs led
2
Collaborators
406
Papers, trials and grants by year

2011: 4 papers · 2012: 6 papers · 2013: 6 papers · 2014: 5 papers · 2015: 3 papers · 2016: 7 papers · 2017: 6 papers · 2018: 13 papers · 2019: 9 papers · 2020: 13 papers · 2021: 12 papers · 2022: 11 papers · 2023: 9 papers · 2024: 4 papers · 2025: 1 paper

Papers 50 of 109

  1. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  2. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Last author DOI 10.1016/j.ejca.2023.113430↗
  3. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  4. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Co-author DOI 10.1245/s10434-024-14951-4↗
  5. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  6. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Co-author DOI 10.1016/j.esmoop.2023.100881↗
  7. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  8. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  9. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  10. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  11. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  12. Independent effect of fat-to-muscle mass ratio at bioimpedance analysis on long-term survival in patients receiving surgery for pancreatic cancer. Co-author DOI 10.3389/fnut.2023.1118616↗
  13. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  14. Preoperative Anxiety in Patients with Pancreatic Cancer: What Contributes to Anxiety Levels in Patients Waiting for Surgical Intervention. Co-author DOI 10.3390/healthcare11142039↗
  15. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. First author DOI 10.1016/j.critrevonc.2021.103571↗
  16. The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic cancer. A prospective observational study … Last author DOI 10.1016/j.pan.2022.10.001↗
  17. Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
  18. Circulating tumour DNA: a challenging innovation to develop "precision onco-surgery" in pancreatic adenocarcinoma. Last author DOI 10.1038/s41416-022-01745-2↗
  19. US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience. Last author DOI 10.1055/a-1178-0474↗
  20. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  21. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗
  22. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  23. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Co-author DOI 10.1245/s10434-022-11417-3↗
  24. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  25. Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy. Co-author DOI 10.4251/wjgo.v14.i3.703↗
  26. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1016/j.annonc.2020.11.013↗
  27. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcin… Co-author DOI 10.1016/j.clon.2020.06.019↗
  28. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  29. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  30. Gα15 in early onset of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-021-94150-3↗
  31. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  32. Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Pr… Co-author DOI 10.1097/sla.0000000000003717↗
  33. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy i… Last author DOI 10.1186/s12885-021-07877-7↗
  34. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  35. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Co-author DOI 10.1200/jco.20.03238↗
  36. Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08658-5↗
  37. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.662205↗
  38. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  39. The emotional impact of surveillance programs for pancreatic cancer on high-risk individuals: A prospective analysis. Co-author DOI 10.1002/pon.5370↗
  40. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution? Last author DOI 10.1007/s13304-020-00798-3↗
  41. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  42. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.04.006↗
  43. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  44. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  45. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  46. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08354-4↗
  47. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  48. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08515-5↗
  49. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to … Last author DOI 10.3389/fonc.2020.600940↗
  50. PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic Cancer Patients Prior to Major Surgery. Co-author DOI 10.3389/fpsyg.2020.00362↗

Closest collaborators

The 25 strongest of 406 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Salvia · 71 shared papers, 2011–2025 · strength 7.22
  2. Giuseppe Malleo · 50 shared papers, 2011–2025 · strength 5.38
  3. Salvatore Paiella · 46 shared papers, 2015–2025 · strength 4.76
  4. Laura Maggino · 22 shared papers, 2017–2023 · strength 2.27
  5. Aldo Scarpa · 25 shared papers, 2011–2025 · strength 2.19
  6. Michèle Milella · 17 shared papers, 2013–2023 · strength 1.77
  7. Mirko D’Onofrio · 22 shared papers, 2011–2025 · strength 1.73
  8. Giovanni Marchegiani · 19 shared papers, 2011–2024 · strength 1.65
  9. Gabriella Lionetto · 11 shared papers, 2021–2025 · strength 1.64
  10. Erica Secchettin · 14 shared papers, 2018–2024 · strength 1.57
  11. Matteo De Pastena · 16 shared papers, 2018–2024 · strength 1.57
  12. Giovanni Butturini · 20 shared papers, 2011–2024 · strength 1.50
  13. Claudio Luchini · 11 shared papers, 2019–2024 · strength 1.44
  14. Isabella M. Frigerio · 16 shared papers, 2012–2024 · strength 1.21
  15. Massimo Falconi · 13 shared papers, 2012–2024 · strength 1.19
  16. Alessandro Esposito · 10 shared papers, 2018–2024 · strength 1.10
  17. Fabio Casciani · 8 shared papers, 2018–2024 · strength 1.06
  18. Roberto Girelli · 13 shared papers, 2012–2022 · strength 0.94
  19. Riccardo De Robertis · 10 shared papers, 2016–2024 · strength 0.86
  20. Alessandro Zerbi · 8 shared papers, 2012–2024 · strength 0.83
  21. Antonio Pea · 7 shared papers, 2019–2023 · strength 0.82
  22. Alessandro Giardino · 11 shared papers, 2012–2022 · strength 0.76
  23. Raffaella Casolino · 7 shared papers, 2017–2023 · strength 0.73
  24. Marta Sandini · 7 shared papers, 2016–2023 · strength 0.71
  25. Darío Gregori · 5 shared papers, 2021–2024 · strength 0.69

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.